Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Multiple Dose Study to Evaluate the Pharmacokinetics of Entospletinib in Subjects With Normal and Impaired Hepatic Function

NCT02521376 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT02521376
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02521376 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Multiple Dose Study to Evaluate the Pharmacokinetics of Entospletinib in Subjects With Normal and Impaired Hepatic Function
Lead sponsor
Gilead Sciences
Phase
Phase 1
Overall status
Completed
Start date
November 16, 2015
Completion date
October 25, 2017
Enrollment
56 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

oncology